Drug studied at UK is 1st disease-modifying therapy in U.S. approved to treat Alzheimer’s
University of KentuckyOn July 6, 2023, the U.S. Food and Drug Administration (FDA) granted full approval to lecanemab, marketed as Leqembi, for the treatment of Alzheimer’s disease. The University of Kentucky’s Sanders-Brown Center on Aging has been working with this drug and others like it for more than a decade.